AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Odonate TherapeuticsOpko HealthOmerosCannTrustMyovant Sciences
SymbolNASDAQ:ODTNASDAQ:OPKNASDAQ:OMEROTCMKTS:CNTTFNYSE:MYOV
Price Information
Current Price$34.12$2.26$14.95N/A$17.75
52 Week RangeHoldBuyBuyN/ABuy
Beat the Market™ Rank
Overall Score1.12.31.51.11.9
Analysis Score1.03.53.30.03.4
Community Score2.12.53.02.62.6
Dividend Score0.00.00.00.00.0
Ownership Score2.04.01.00.03.0
Earnings & Valuation Score0.61.30.03.10.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyN/ABuy
Consensus Price Target$26.00$3.17$25.33N/A$27.00
% Upside from Price Target-23.80% downside40.12% upside69.45% upsideN/A52.11% upside
Trade Information
Market Cap$1.09 billion$1.59 billion$811.11 million$67.40 million$1.50 billion
Beta1.112.251.884.522.55
Average Volume75,99113,207,535681,712N/A1,034,027
Sales & Book Value
Annual RevenueN/A$901.90 million$111.81 million$15.96 millionN/A
Price / SalesN/A1.687.290.00N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.06 per share$2.43 per share($2.19) per shareN/A($1.21) per share
Price / BookN/A0.93-6.83NaNN/A
Profitability
Net Income$-111,820,000.00$-314,920,000.00$-84,490,000.00N/A$-288,990,000.00
EPS($4.05)($0.41)($0.96)$0.07($3.37)
Trailing P/E RatioN/AN/AN/A9.11N/A
Forward P/E RatioN/AN/AN/A0.00N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-32.92%-78.52%N/AN/A
Return on Equity (ROE)-67.21%-13.56%N/AN/A-2,288.94%
Return on Assets (ROA)-58.26%-9.43%-58.57%N/A-172.45%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.16%N/AN/A5.88%
Current Ratio6.28%1.12%1.48%N/A1.02%
Quick Ratio6.28%0.88%1.46%N/A1.02%
Ownership Information
Institutional Ownership Percentage95.78%23.68%57.44%0.08%34.22%
Insider Ownership Percentage48.90%40.90%11.30%N/A3.68%
Miscellaneous
Employees1176,096236N/A86
Shares Outstanding32.11 million669.83 million54.51 million105.64 million89.87 million
Next Earnings Date7/22/2020 (Estimated)8/5/2020 (Estimated)8/13/2020 (Estimated)N/A8/4/2020 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.